Seelos Therapeutics Inc
NASDAQ:SEEL
Seelos Therapeutics Inc
NASDAQ:SEEL
Price:
0.3 USD
7.53%
Market Closed
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
SEEL
stock under the Base Case scenario is
0.4
USD.
Compared to the current market price of 0.3 USD,
Seelos Therapeutics Inc
is
Undervalued by 24%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SEEL
Relative Value
Base Case
0.4
USD
Undervaluation 24%
Valuation Multiples
Multiples Across Competitors
SEEL Competitors Multiples
Seelos Therapeutics Inc Competitors
Seelos Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Seelos Therapeutics Inc
NASDAQ:SEEL
|
4.1m USD | 1.9 | -0.1 | -0 | -0 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
737.4B USD | 21.6 | 140.7 | 63.5 | 72.9 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 16.9 | 47.2 | 34.3 | 37.4 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| JP |
|
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 255.8 | 9 733.7 | 1 771.8 | 4 320.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
363.9B USD | 4.4 | 9 | 12 | 15.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
326.1B USD | 5.3 | 141.4 | 33.6 | 53.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
189.7B GBP | 5.2 | 39.8 | 140.8 | 225.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.5B CHF | 4.3 | 13.4 | 9.8 | 16.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
175.5B CHF | 3 | 15.3 | 8.7 | 10.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
